Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype

Laura Z. Vanags, PhD; Joanne T.M. Tan, PhD; Keyvan K. Galougahi, MD, PhD; Andreas Schaefer, MD; Steven G. Wise, PhD; Andrew Murphy, PhD; Ziad A. Ali, MD, PhD; Christina A. Bursill, PhD

JACC: Basic to Translational Science (Apr 2018)

Apolipoprotein A-I Reduces In-Stent Restenosis and Platelet Activation and Alters Neointimal Cellular Phenotype

Laura Z. Vanags, PhD,
Joanne T.M. Tan, PhD,
Keyvan K. Galougahi, MD, PhD,
Andreas Schaefer, MD,
Steven G. Wise, PhD,
Andrew Murphy, PhD,
Ziad A. Ali, MD, PhD,
Christina A. Bursill, PhD

Affiliations

Laura Z. Vanags, PhD: Immunobiology Group, The Heart Research Institute, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia
Joanne T.M. Tan, PhD: Immunobiology Group, The Heart Research Institute, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia
Keyvan K. Galougahi, MD, PhD: Center for Interventional Vascular Therapy, Columbia University, New York, New York; Cardiovascular Research Foundation, New York, New York
Andreas Schaefer, MD: Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
Steven G. Wise, PhD: Immunobiology Group, The Heart Research Institute, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia
Andrew Murphy, PhD: Haematopoiesis and Leukocyte Biology Group, Baker IDI Heart and Diabetes Institute, Melbourne, Australia; Department of Immunology, Monash University, Melbourne, Australia
Ziad A. Ali, MD, PhD: Center for Interventional Vascular Therapy, Columbia University, New York, New York; Cardiovascular Research Foundation, New York, New York
Christina A. Bursill, PhD: Immunobiology Group, The Heart Research Institute, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia; Address for correspondence: Dr. Christina Bursill, Heart Health Theme, South Australia Health and Medical Research Institute, North Terrace, Adelaide, South Australia 5000, Australia.

Journal volume & issue: Vol. 3, no. 2
pp. 200 – 209

Abstract

Read online

Summary: Even the most advanced drug-eluting stents evoke unresolved issues, including chronic inflammation, late thrombosis, and neoatherosclerosis. This highlights the need for novel strategies that improve stent biocompatibility. Our studies show that apolipoprotein A-I (apoA-I) reduces in-stent restenosis and platelet activation, and enhances endothelialization. These findings have therapeutic implications for improving stent biocompatibility. Key Words: apolipoprotein A-I, endothelialization, neointimal hyperplasia, platelet activation, stent biocompatibility

Published in JACC: Basic to Translational Science

ISSN: 2452-302X (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://www.journals.elsevier.com/jacc-basic-to-translational-science/

About the journal